| 2008 - 2013 | 2nd generation Vaccibodies for infectious diseases | Bjarne Bogen |
| 2009 - 2013 | A rapid serological screening method for detecting tuberculosis disease and monitoring the efficacy of new vaccines | Carol Holm-Hansen |
| 2008 - 2011 | Accessibility to health services among people with disabilities in southern Africa | Arne Henning Eide |
| 2010 - 2012 | Additional activities related to an ongoing project: Impact of the new vaccine MenAfriVac on carriage of serogroup A Neisseria m | Dominique A. Caugant |
| 2010 - 2014 | Advancing Rotavirus Vaccine Development (ARVAC) - BBIL Phase 3 Study | John Boslego |
| 2006 - 2010 | Alternative Treatment Strategies in HIV Infection - research platform with integrated biological and clinical objectives | Dag Kvale |
| 2009 - 2013 | Application of Open Source Licensing to Vaccine and Medicine Discovery and Development | Atle Fretheim |
| 2010 - 2013 | Biomarkers of mycobacterial infection and disease, and molecular characterization of mycobacteria from high TB-burden countries. | Ruth Stavrum |
| 2010 - 2013 | 'Communicate to vaccinate': Building evidence for improving communication about childhood vaccinations in low- and middle-income | Simon Lewin |
| 2008 - 2013 | Developing vaccines against diarrhea caused by Enterotoxigenic Escherichia coli and Shigella (EntVac) | Halvor Sommerfelt |
| 2006 - 2008 | Development and validation of delivery technology for gene based prophylactic vaccines | Iacob Mathiesen |
| 2010 - 2013 | Development of a food-grade Lactobacillus-based oral vaccine delivery system | Vincent Eijsink |
| 2009 - 2010 | Development of a proposal on Norwegian engagement and collaborative projects in a phase III trial of oral rotavirus vaccine ORV | Tor Arne Strand |
| 2006 - 2009 | Development of a subunit vaccine for prevention of reactivation of tuberculosis | Harald G. Wiker |
| 2009 - 2013 | Development of an outer membrane vesicle vaccine for Africa against serogroup A and W-135 meningococcal disease | Lisbeth Meyer Næss |
| 2012 - 2014 | Development of biodegradable nanobeads as vaccines against tuberculosis. | Gareth Griffiths |
| 2009 - 2013 | Development of novel vaccine candidates to prevent primary or reactivated tuberculosis | Harald G. Wiker |
| 2008 - 2012 | Evaluation of the Impact of the Integrated Management of Neonatal and Childhood Illness Strategy on Neonatal and Infant Mortalit | Halvor Sommerfelt |
| 2007 - 2007 | Explaining Differential Immunization Coverage: a multi-disciplinary approach | Sidsel Roalkvam |
| 2009 - 2014 | Expression and evaluation of envelope domain III-based experimental tetravalent dengue vaccine using tobacco chloroplast express | Jihong Liu Clarke |
| 2006 - 2013 | Focus on Nutrition and Child Health: Intervention Studies in Low-income Countries | Tor Arne Strand |
| 2007 - 2013 | Further Developments of New Immunogenic Peptide-based HIV Vaccines Targeting Dendritic Cells | Dag Kvale |
| 2010 - 2013 | Health systems strengthening within vaccination programmes: an ethnographic study (HEALVAC) | Sidsel Roalkvam |
| 2008 - 2012 | HIV vulnerability and HIV prevention needs among men who have sex with men in Tanzania | Anne-Lise Middelthon |
| 2010 - 2014 | IgA antibodies in saliva as a noninvasive readout for intestinal immune responses | Per Brandtzæg |
| 2007 - 2013 | Immunity towards mycobacteria - identification of avirulent vaccine strains and therapeutic targets | Trude Helen Flo |
| 2008 - 2011 | Impact of a new and affordable conjugate meningococcal vaccine on carriage of serogroup A Neisseria meningitidis and disease tra | Dominique A. Caugant |
| 2009 - 2013 | Improved vaccination responses and optional immunomodulating therapy by adjuvant administration of COX-2 inhibitor in HIV-infect | Dag Kvale |
| 2008 - 2012 | IMPROVING DIAGNOSIS, TREATMENT AND CONTROL OF CHILDHOOD TUBERCULOSIS | Harleen Grewal |
| 2008 - 2012 | Indoor air pollution. A neglected poverty related cause of global ill health -impl. for health and society of promoting clean fu | Kristin Aunan |
